Edwards Lifesciences Corporation EW
NYSE
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -1.46% | 5.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.46% | 5.60% | |||
| Cost of Revenue | -5.91% | 8.22% | |||
| Gross Profit | -0.17% | 4.87% | |||
| SG&A Expenses | -0.05% | 7.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -20.91% | 22.54% | |||
| Total Operating Expenses | -1.91% | 7.73% | |||
| Operating Income | -0.42% | 0.93% | |||
| Income Before Tax | -30.13% | 13.25% | |||
| Income Tax Expenses | -77.80% | 255.56% | |||
| Earnings from Continuing Operations | 24.86% | -36.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 1,120.00% | -- | |||
| Net Income | 27.12% | -36.46% | |||
| EBIT | -0.42% | 0.93% | |||
| EBITDA | 0.00% | 1.19% | |||
| EPS Basic | 27.14% | -36.15% | |||
| Normalized Basic EPS | 11.48% | -14.77% | |||
| EPS Diluted | 26.28% | -36.15% | |||
| Normalized Diluted EPS | 11.46% | -14.73% | |||
| Average Basic Shares Outstanding | -0.02% | -0.48% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||